BIIB — Biogen Inc.

Biogen (BIIB) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $2.5 billion, up 2% year-over-year.
• GAAP Diluted EPS: $2.15, up 31% year-over-year.
• Non-GAAP Diluted EPS: $3.57, up 18% year-over-year.
• Growth Products Revenue: $851 million, up 12% year-over-year, with LEQEMBI revenue at $168 million (up 74% year-over-year).
• Free Cash Flow: $594 million for the quarter.
• Cash and Marketable Securities: $4.7 billion, with $1.5 billion in net debt.

2. Strategic Updates and Business Highlights

• Biogen has stabilized its business after four years of declining revenue and profit, focusing on investing for growth rather than just cost-cutting.
• The company has shifted commercial costs towards growth products, leading to increased revenue from these areas.
• The approval of high-dose SPINRAZA is expected to enhance competitiveness and patient retention.
• LEQEMBI's care pathway has been improved, with a new subcutaneous formulation awaiting FDA approval (PDUFA date: May 24).
• Biogen is pursuing the acquisition of Apellis Pharmaceuticals, which is expected to close in Q2 2026, enhancing its portfolio in immunology and rare diseases.

3. Forward Guidance and Outlook

• Biogen expects the Apellis acquisition to be accretive to EPS in 2027 and to materially increase its EPS outlook.
• The company anticipates continued growth in its pipeline, with multiple data readouts expected through 2026 and beyond.
• Guidance remains consistent with prior expectations, with anticipated contract manufacturing revenue of approximately $600 million in 2026.

4. Bad News, Challenges, or Points of Concern

• SPINRAZA's revenue decline is attributed to shipment timing, indicating potential volatility in revenue streams.
• The competitive landscape in ophthalmology, particularly for SYFOVRE, poses risks as other companies develop products targeting visual acuity rather than lesion burden.
• The need for ongoing investment in R&D and marketing may pressure margins, especially with the integration of Apellis.
• The company faces challenges in recruiting for clinical trials in nephrology due to increased competition from other firms.

5. Notable Q&A Insights

• BIIB080: The upcoming Phase II results are critical for determining the next steps in development, with a focus on tau reduction and its correlation with clinical benefits.
• LEQEMBI: There is optimism about the adoption of blood-based biomarkers and the potential for improved treatment persistence with the new subcutaneous formulation.
• SYFOVRE: The competitive landscape is evolving, and Biogen plans to leverage its existing capabilities to maximize the product's market potential.
• Felzartamab: The acquisition of China rights is seen as a significant opportunity, with expectations of substantial market potential in the nephrology space.

Overall, Biogen reported a solid quarter with positive growth in key areas, while also navigating challenges in a competitive landscape and preparing for strategic acquisitions.